ROIV
Roivant Sciences Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow -6.0% ·
net new positions +6.2%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 129 | +11 | 407.19M | $14.42B | +15 | −5 |
| Q1 2026 | 122 | +5 | 384.63M | $10.65B | +13 | −9 |
| Q4 2025 | 117 | +1 | 374.22M | $8.12B | +3 | −1 |
| Q3 2025 | 19 | +1 | 262.46M | $3.97B | +1 | −1 |
| Q2 2025 | 16 | +1 | 211.12M | $2.38B | +1 | — |
| Q1 2025 | 12 | +1 | 89.39M | $901.93M | +2 | −1 |
| Q4 2024 | 11 | -2 | 96.86M | $1.15B | — | −2 |
| Q3 2024 | 12 | -1 | 85.45M | $986.08M | +1 | −2 |
| Q2 2024 | 13 | — | 92.40M | $976.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 55.51M | — | $625.59M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 40.32M | — | $454.36M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 3 | The Vanguard Group ✦ (passive) | 39.33M | — | $443.21M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Viking Global Investors ✦ | 34.24M | -25.6% | $385.86M | 1.1% | ▼ Trim | 5 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 19.77M | +4.8% | $222.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 7.75M | -2.7% | $87.36M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | Greenlight Capital (DME Capital) ✦ | 4.55M | -16.4% | $51.29M | 2.2% | ▼ Trim | 5 | SEC ↗ ×3 |
| 8 | Point72 Asset Management ✦ | 2.95M | +380.4% | $33.26M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 2.08M | -45.5% | $23.47M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 1.47M | +463.6% | $16.58M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 965.97K | +493.5% | $10.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Marshall Wace ✦ | 955.15K | +251.4% | $10.76M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Norges Bank ✦ (passive) | 616.87K | -86.5% | $6.95M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 492.13K | -63.6% | $5.55M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 83.68K | New | $943,119 | 0.0% | New | 1 | SEC ↗ ×2 |
| 16 | Gotham Asset Management ✦ | 39.15K | +0.3% | $441,209 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $943,119 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 436 holders, 528.48M shares, $14.35B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 900 sh · $32,913
Director · 16.85K sh · $607,948
Director · 600 sh · $24,228
Director · 400 sh · $16,180
Director · 4.34K sh · $172,002
Director · 4.71K sh · $186,972
Director · 20.00K sh · $798,000
Officer · 33.82K sh · $1.23M
Officer · 166.18K sh · $5.92M
Officer, Director · 144.76K sh · $5.28M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology